A possible mechanism of hyperlipidemia in a patient with metastatic non-small cell lung cancer on lorlatinib therapy.

Katherine McGeeNeil J StoneShikha WadhwaniYashpal S KanwarVictoria VillaflorNausheen Akhter

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2021)

This is a case of hyperlipidemia in a patient on lorlatinib. The case highlights that therapies for lung cancer and other malignancies have the potential to alter the lipid profile. We propose minimal change disease as a possible mechanism for lorlatinib-induced dyslipidemia. Additionally, we discuss the crucial aspects of secondary hyperlipidemia workup.

Keyphrases

high fat diet
case report
squamous cell carcinoma
small cell lung cancer
high fat diet induced
high glucose
stem cells
diabetic rats
insulin resistance
metabolic syndrome
drug induced
oxidative stress
climate change
human health
cell therapy
skeletal muscle
stress induced
smoking cessation